Show simple item record

dc.contributor.authorDearden, CE
dc.contributor.authorMatutes, E
dc.date.accessioned2018-09-04T11:47:31Z
dc.date.issued2006
dc.identifier4
dc.identifier.citationBEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2006, 19 pp. 795 - 810
dc.identifier.issn1521-6926
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2533
dc.identifier.doi10.1016/j.beha.2006.05.005
dc.description.abstractThe humanized monoclonal antibody alemtuzumab binds to the CD52 antigen, a glycoprotein which is widely expressed on normal and malignant B and T lymphocytes. Recently it has been demonstrated in a number of clinical trials that alemtuzumab has clinical activity in mature T-cell diseases such as T-prolymphocytic leukaemia and cutaneous T-cell lymphoma, inducing responses in up to two thirds of heavily pre-treated relapsed/refractory patients. Response was associated with improved survival. The toxicity profile for the antibody is manageable. The major complications are infusional reactions associated with initial injections, and prolonged lymphopenia associated with reactivation of viruses. Future studies will be directed towards alternative (subcutaneous) routes and schedules of administration, use as first-line therapy, combination strategies, and role of alemtuzumab to purge minimal residual bone-marrow disease prior to stem-cell transplantation.
dc.format.extent795 - 810
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE BV
dc.titleAlemtuzumab in T-cell lymphoproliferative disorders
dc.typeJournal Article
rioxxterms.versionofrecord10.1016/j.beha.2006.05.005
rioxxterms.licenseref.startdate2006
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
pubs.notesaffiliation: Dearden, CE (Reprint Author), Royal Marsden NHS Fdn Trust, Downs Rd, Sutton SM2 5PT, Surrey, England. Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England. keywords: T cell; alemtuzumab keywords-plus: ANTI-CD52 MONOCLONAL-ANTIBODY; GRANULAR LYMPHOCYTE LEUKEMIA; MYCOSIS FUNGOIDES/SEZARY-SYNDROME; PHASE-II TRIAL; NON-HODGKIN LYMPHOMA; SEZARY-SYNDROME; PROLYMPHOCYTIC LEUKEMIA; REMISSION INDUCTION; COMPLETE RESPONSE; CARDIAC TOXICITY research-areas: Hematology web-of-science-categories: Hematology author-email: [email protected] number-of-cited-references: 67 times-cited: 23 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Best Pract. Res. Clin. Haematol. doc-delivery-number: 096UZ unique-id: ISI:000241403600012 da: 2018-09-04
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular Haematology (including Cytogenetics Group and Cell Markers)
pubs.volume19
pubs.embargo.termsNot known
icr.researchteamMolecular Haematology (including Cytogenetics Group and Cell Markers)en_US
dc.contributor.icrauthorMatutes, Estellaen
dc.contributor.icrauthorDearden, Claireen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record